EUVIMEDEUVIMED entdecken
Crossref

High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma

Hideki Sasanuma, Yoshiyuki Meguro, Kentaro Shimodaira, Masatake Taniguchi, Yuki Kimura, Yuichi Aoki, Masanobu Taguchi, Naoya Kasahara, Kazue Morishima, Yuji Kaneda, Atsushi Miki, Kazuhiro Endo und 6 weitere

Oncology · 2025

DOI: 10.1159/000550192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Hideki Sasanuma und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke, Japan, h-ssnm@jichi.ac.…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. While curative resection offers the best chance for long-term survival, the high postoperative recurrence rate suggests a persistent need for effective perioperative therapies. We investigated a multimodal approach, combining sequential lenvatinib with transarterial chemoembolization (TACE), as a presurgical treatment (PST) for resectable HCC.

Methods

This retrospective study included 19 patients with technically resectable HCC who underwent the PST protocol followed by surgery between March 2022 and September 2024. The protocol involved four phases: Pre-TACE lenvatinib administration (Pre-LEN), TACE, Post-TACE lenvatinib administration, and surgery. We assessed the feasibility, safety, and pathological response of the protocol. Liver function was evaluated using the albumin-bilirubin (ALBI) score, modified ALBI (mALBI) grade, and tumor response was assessed using the Response Evaluation Criteria in Cancer of the Liver (RECICL).

Results

The PST protocol demonstrated high efficacy and safety. The median tumor reduction rate was 22.9%, and the median pathological tumor necrosis rate was 95%. The preoperative overall RECICL response was a complete response in 84.2% of patients. With a median follow-up of 22 months, the 2-year recurrence-free survival rate was 84.6%, and the overall survival rate was 100%. A significant association was found between mALBI grade and the decision to proceed with surgery at two time points: Pre-LEN (p = 0.023) and before surgery (p = 0.006).

Conclusion

Presurgical sequential lenvatinib-TACE therapy is a feasible and safe strategy for resectable HCC. This protocol achieved a high pathological response and favorable survival outcomes, suggesting that it may mitigate the risk of early recurrence. Our findings highlight the importance of mALBI grade monitoring for patient selection and provide a rationale for larger, prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesChemoembolization, TherapeuticAntineoplastic AgentsHumansFemaleMaleAgedRetrospective StudiesMiddle AgedTreatment OutcomeNeoplasm Recurrence, LocalNeoadjuvant Therapy

Stichwörter der Autor:innen

Hepatocellular carcinomaLenvatinibNeoadjuvant therapyPathological responsePresurgical treatmentSurgeryTransarterial chemoembolization

Substanzen

Phenylurea CompoundsQuinolineslenvatinibAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke, Japan, h-ssnm@jichi.ac.jp.
  • Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke, Japan.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Radiology, Jichi Medical University, Shimotsuke, Japan.

Zitieren

APA

Sasanuma, H., Meguro, Y., Shimodaira, K., Taniguchi, M., Kimura, Y., Aoki, Y., Taguchi, M., Kasahara, N., Morishima, K., Kaneda, Y., Miki, A., Endo, K., Watanabe, S., Hamamoto, K., Sakuma, Y., Morimoto, N., Yamaguchi, H., & Sata, N. (2025). High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000550192

Vancouver

Sasanuma H, Meguro Y, Shimodaira K, Taniguchi M, Kimura Y, Aoki Y, et al. High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma. Oncology. 2025. doi:10.1159/000550192

BibTeX
@article{Sasanuma2025,
  author = {Sasanuma, Hideki and Meguro, Yoshiyuki and Shimodaira, Kentaro and Taniguchi, Masatake and Kimura, Yuki and Aoki, Yuichi and Taguchi, Masanobu and Kasahara, Naoya and Morishima, Kazue and Kaneda, Yuji and Miki, Atsushi and Endo, Kazuhiro and Watanabe, Shunji and Hamamoto, Kohei and Sakuma, Yasunaru and Morimoto, Naoki and Yamaguchi, Hironori and Sata, Naohiro},
  title = {High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000550192}
}
Kostenlos starten →